Exclusive Interviews

In part one of this special interview, Dr. Stanley Schwartz and DIC publisher Steve Freed discuss Dr. Schwartz's proposed new beta-cell centric classification of diabetes.

In part two of this special interview, Dr. Schwartz discusses the "egregious eleven" -- six mechanisms that injure the beta cell, and five results of injury -- and the role they play in hyperglycemia.

In part three of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses how the new beta-cell classification supports a patient-centric, "precision medicine" approach to diabetes care, and enables more targeted treatments for hyperglycemia.

In part four of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses the need for better markers in improving individualization of diabetes patient care.

In part five of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses in-depth the mechanisms by which beta cell damage contributes to hyperglycemia and the targeted treatments for mediating pathways of hyperglycemia.

In part six of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses the role of gene defects within the beta cell in monogenic diabetes. In terms of prediabetes, since beta cell damage exists before the development of diabetes, better markers may help in prevention.

In part seven of this special interview with DIC publisher Steve Freed, Dr. Stanley Schwartz discusses the supporters of the new classification of diabetes, such as the role of SGLT-2 inhibitors in improving cardiovascular outcomes, reducing weight, and targeting treatments for the mediating pathways of hyperglycemia.

In part three of this exclusive interview, Dr. Don Fetterolf talks about the use of amniotic membrane in the healing of diabetic foot ulcers and the process of using the placenta to create the graphs.

In part two of this discussion, hosted by Diabetes in Control Publisher Steve Freed, Dr. Fetterolf continues his explanation of the best treatments for diabetic foot ulcers and the additional challenges that patients with diabetes face.

In part one of this interview on the use of amniotic membrane as a possible treatment for diabetic ulcers, Diabetes in Control publisher first talks with Dr. Don Fetterolf about the prevalence of diabetic foot ulcers, the impact of the condition and the groups who are affected.